Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.

Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR.

J Urol. 2010 Jun;183(6):2200-5. doi: 10.1016/j.juro.2010.02.022.

2.

Bone health management in prostate cancer patients receiving androgen deprivation therapy.

Dhanapal V, Reeves DJ.

J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105.

PMID:
21807761
3.

Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.

James H 3rd, Aleksic I, Bienz MN, Pieczonka C, Iannotta P, Albala D, Mariados N, Mouraviev V, Saad F.

Urology. 2014 Jul;84(1):164-8. doi: 10.1016/j.urology.2013.12.071.

PMID:
24976229
4.

Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.

Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L.

J Urol. 2010 Sep;184(3):918-23. doi: 10.1016/j.juro.2010.04.068.

PMID:
20643458
5.

Risk of fracture after androgen deprivation for prostate cancer.

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS.

N Engl J Med. 2005 Jan 13;352(2):154-64.

7.

Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group..

N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003.

8.

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL.

BJU Int. 2013 May;111(5):745-52. doi: 10.1111/j.1464-410X.2012.11758.x.

9.

Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.

Adler RA, Hastings FW, Petkov VI.

Osteoporos Int. 2010 Apr;21(4):647-53. doi: 10.1007/s00198-009-0984-0.

PMID:
19533207
10.

Fracture risk in Danish men with prostate cancer: a nationwide register study.

Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K.

BJU Int. 2007 Oct;100(4):749-54.

11.

Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment.

Graham-Steed TR, Soulos PR, Dearing N, Concato J, Tinetti ME, Gross CP.

J Geriatr Oncol. 2014 Oct 1;5(4):343-51. doi: 10.1016/j.jgo.2014.08.004.

12.
13.

Androgen deprivation therapy for prostate cancer: new concepts and concerns.

Smith MR.

Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):247-54. Review.

14.

Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.

Siris ES, Baim S, Nattiv A.

Postgrad Med. 2010 Jan;122(1):82-90. doi: 10.3810/pgm.2010.01.2102. Review.

PMID:
20107292
15.

Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.

Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.

Int J Urol. 2007 Dec;14(12):1071-5.

16.

Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.

Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MR.

J Urol. 2012 Mar;187(3):889-93. doi: 10.1016/j.juro.2011.10.136.

17.

The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice.

Watts NB.

J Womens Health (Larchmt). 2011 Apr;20(4):525-31. doi: 10.1089/jwh.2010.2294.

PMID:
21438699
18.

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.

J Clin Oncol. 2007 Mar 20;25(9):1038-42.

19.

Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer.

Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR.

J Urol. 2011 Aug;186(2):482-6. doi: 10.1016/j.juro.2011.03.111.

20.

Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.

Beebe-Dimmer JL, Cetin K, Shahinian V, Morgenstern H, Yee C, Schwartz KL, Acquavella J.

Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):70-8. doi: 10.1002/pds.2258.

Items per page

Supplemental Content

Support Center